Actionable news
All posts from Actionable news
Actionable news in XBIT: XBiotech Inc,

XBiotech Colon Cancer Drug Data Deemed Unreliable by European Group

Results from a phase III study of Xylonix, a colon cancer drug developed by XBiotech (XBIT) , have been deemed unreliable by the European Society of Medical Oncology (ESMO), according to a statement issued Thursday.

Serious questions about the XBiotech colon cancer drug were raised after the Xylonix presentation at an ESMO cancer meeting on July 2.

These questions prompted ESMO to review the XBiotech...